Patent · US Active

PUMA, a pro-apoptotic gene, as a novel molecular biomarker for TNFα-induced human islet damage

US9758826B2 · kind B2 · utility

0Cited by
0References
6Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 17, 2011
Grant dateSep 12, 2017
Priority date
Expiry dateJun 17, 2031

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/525
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-α stimulation in a time- and dose-dependent manner and β cell apoptosis is induced through a mitochondrial pathway. TNF-α significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such β cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.